Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

NCT01948830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: Ranibizumab 0.5mg
DRUG: Ranibizumab 0.5mg

Sponsor

Novartis Pharmaceuticals